TNF-alpha, Human, mAb 5N
The monoclonal antibody 5N reacts with Tumor Necrosis Factor alpha (TNF-alpha). Tumor necrosis factor-alpha (TNF-alpha), a homotrimeric 17 KD protein, is a potent mediator of inflammatory and metabolic functions. TNF-alpha was originally detected as a highly cytotoxic cytokine for tumor cells, it causes tumor necrosis in vivo and shows cytolytic activity against tumor cells in vitro. Further TNF-alpha has been implied as central mediator in shock induced by gram negative micro-organisms. The cytokine TNF-alpha is found to be a central mediator in many inflammatory and immunological processes: it can be induced by various products of micro-organisms and by various cytokines but it also induces on its turn the production of many cytokines. Signal transduction occurs via two types of TNF-receptors, the TNF-receptors I and II. The receptors differ strongly in their intra-cellular signaling pathways. The TNF-alpha trimer interacts with either of the two types of TNF-R leading to receptor cross-linking. The monoclonal antibody 5N cross-reacts and cross-neutralizes all monkey species TNF-alpha, except pig-tail macaque. With affinity about two orders lower it recognizes bovine and canine TNF-alpha.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- Discover Cross-Reactive Complement ELISA for NHP ResearchBridging Human and NHP Complement Research. At Hycult Biotech, we understand the importance of testing therapeutic agents on non-human primates (NHP) samples in order to get approval to enter clinical phases. That is why we have committed to the following initiative: Testing our existing complement ELISA assays for NHP research. Why Non Human Primate Samples… Read more: Discover Cross-Reactive Complement ELISA for NHP Research
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis